AIVITA Biomedical, Inc.

12:15 PM - 12:30 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of COVID-19 and treatment of cancer. We take a unique pan-antigenic approach for our cancer vaccine — targeting all neoantigens, rather than a select few — allowing our treatment to overcome cancer’s tendency to mutate over time. Utilizing our autologous cell therapy platform, which has generated multiple therapeutic vaccine programs shown to be safe and effective in early clinical trials, we are developing a personalized vaccine with adaptive immunity against COVID-19. Our unique expertise in stem cell growth and directed, high-purity differentiation enables us to develop safe, efficient and economical manufacturing processes for therapeutic development.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Personalized immunotherapy for the treatment of GBM
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chairman of the Board
Immunis, Inc.